title: [Treatment of primary Sjögren syndrome].
abstract: Treatment of primary Sjögren's syndrome is adapted to the initial evaluation of symptom and extraglandular manifestation according to the damage/activity ratio. Symptomatic treatment is systematic, whereas systemic treatment is limited to the active extra glandular forms. There is no international treatment consensus. Biologics are currently evaluated.
authors.affiliation: Service de rhumatologie et laboratoire d'immunologie, CHU de la Cavale-Blanche, 29609 Brest Cedex. alain.saraux@chu-brest.fr
authors.forename: Alain
authors.initials: A
authors.lastname: Saraux
authors.forename: Sandrine
authors.initials: S
authors.lastname: Jousse-Joulin
authors.forename: Valérie
authors.initials: V
authors.lastname: Devauchelle-Pensec
mesh_terms: D053264:B-Cell Activating Factor / Q000276:immunology; D005221:Fatigue / Q000209:etiology / Q000628:therapy; D006801:Humans; D010146:Pain / Q000209:etiology; D059408:Pain Management / Q000379:methods; D011115:Polyneuropathies / Q000209:etiology / Q000628:therapy; D012466:Salivary Gland Diseases / Q000209:etiology / Q000628:therapy; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D012859:Sjogren's Syndrome / Q000150:complications / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D053264:B-Cell Activating Factor; D051918:Sialic Acid Binding Ig-like Lectin 2; C505719:TNFSF13B protein, human; D014409:Tumor Necrosis Factor-alpha